Healthcare · Biotechnology
Price
$1.47
Market Cap
$1.3M
Employees
1
Beta
3.29
Avg Volume
3,046,942
CEO
James Nathanielsz
Business Description
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
0.00
Stock Price: $1.47
EPS (Diluted): -371.25
EPS (Diluted): -371.25
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.18
Stock Price: $1.47
Total Equity: $13.91M
Shares: 158,727
Total Equity: $13.91M
Shares: 158,727
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.31
Market Cap: $1.29M
Total Debt: $1.67M
Cash: $12,088
EBITDA: -$58.34M
Total Debt: $1.67M
Cash: $12,088
EBITDA: -$58.34M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$18.2M
Market Cap: $1.29M
Total Debt: $1.67M
Cash: $12,088
Total Debt: $1.67M
Cash: $12,088
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.47
Revenue: $0.00
Shares: 158,727
Revenue: $0.00
Shares: 158,727
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$57.28M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$58.92M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-423.7%
Net Income: -$58.92M
Total Equity: $13.91M
Total Equity: $13.91M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-368.1%
Operating Income: -$57.28M
Tax Rate: 0.0%
Equity: $13.91M
Total Debt: $1.67M
Cash: $12,088
Tax Rate: 0.0%
Equity: $13.91M
Total Debt: $1.67M
Cash: $12,088
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.50
Current Assets: $8.35M
Current Liabilities: $5.58M
Current Liabilities: $5.58M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.12
Short-Term Debt: $1.56M
Long-Term Debt: $105,627
Total Debt: $1.67M
Total Equity: $13.91M
Long-Term Debt: $105,627
Total Debt: $1.67M
Total Equity: $13.91M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 158,727
Shares: 158,727
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$87.61
Total Equity: $13.91M
Shares: 158,727
Shares: 158,727
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-2.55
Operating CF: -$405,168
CapEx: -$2.00
Shares: 158,727
CapEx: -$2.00
Shares: 158,727
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.47
Stock Price: $1.47
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$58.92M
Net Income: -$58.92M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PPCB against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 6:30am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $17,760 | $21,656 | $0 |
| Gross Profit | $0 | $-5,671 | $-17,760 | $-21,656 | $0 |
| Operating Expenses | $1.8M | $2.0M | $1.8M | $1.5M | $57.3M |
| Operating Income | -$1.8M | -$2.0M | -$1.8M | -$1.5M | -$57.3M |
| Net Income | -$2.0M | -$2.7M | -$2.7M | -$1.8M | -$58.9M |
| EBITDA | -$1.7M | -$2.1M | -$2.2M | -$1.3M | -$58.3M |
| EPS | $-20,000.00 | $-27,986,891.75 | $-781,709.75 | $-35,523.75 | $-371.25 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 6:30am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2,255 | $4,067 | $10,047 | $21,085 | $12,088 |
| Total Current Assets | $6,596 | $15,030 | $19,039 | $25,441 | $8.4M |
| Total Assets | $13,101 | $81,651 | $60,328 | $72,365 | $19.6M |
| Current Liabilities | $3.1M | $3.1M | $3.2M | $3.8M | $5.6M |
| Long-Term Debt | $0 | $0 | $0 | $58,642 | $105,627 |
| Total Liabilities | $3.1M | $3.1M | $3.2M | $3.9M | $5.7M |
| Total Equity | -$3.1M | -$3.0M | -$3.1M | -$3.8M | $13.9M |
| Retained Earnings | -$58.2M | -$61.6M | -$64.7M | -$66.7M | -$125.6M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 6:30am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M | -$1.4M | -$1.1M | $-935,118 | $-405,168 |
| Capital Expenditure | $4 | $4 | $1 | $-2 | $-2 |
| Free Cash Flow | -$1.1M | -$1.4M | -$1.1M | $-935,118 | $-405,168 |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-64,752 | $1,812 | $5,980 | $11,038 | $-8,997 |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 6:30am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | -213.2% | -21.9% | +100.0% |
| Operating Income Growth | -9.9% | +10.7% | +13.6% | -3,629.0% |
| Net Income Growth | -31.2% | -0.1% | +31.6% | -3,135.8% |
| EBITDA Growth | -26.7% | -4.5% | +43.5% | -4,522.8% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for PPCB — it's generated by the pipeline (
market-narrative step).
No community reviews yet for PPCB.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30